The role of serum lactate dehydrogenase / pleural fluid adenosine deaminase ratio and cancer ratio plus in the diagnosis of malignant pleural effusion: A retrospective study
Keywords:
malignant pleural effusion, tuberculous pleural effusion, cancer ratio plus, cancer ratio, parapneumonic effusion, cellblockAbstract
Background: While serum LDH to pleural fluid ADA ratio (sLDH/pADA) and CRp, as calculated by dividing sLDH/pADA by the percentage of pleural fluid lymphocytes, show potential in identifying malignant pleural effusion (MPE), their diagnostic value in tuberculosis-endemic countries remains unclear. Aims: This study assessed their utility in distinguishing MPE among patients with exudative pleural effusion (PE).
Methods: This retrospective study was conducted at Department of Pulmonary Medicine, Cho Ray Hospital (Vietnam) from January 2023 to June 2024, including patients with PE who met the inclusion criteria. All patients underwent blind pleural biopsy or pleural fluid cellblock analysis to confirm or exclude MPE. Clinical, laboratory, and pleural fluid data were collected. The optimal cut-off values, AUC, sensitivity, and specificity of sLDH/pADA and CRp were calculated to diagnose MPE.
Results: 204 patients with exudative PE were classified into MPE (n=119, 58.3%) and non-MPE (n=85, 41.7%) groups. Compared to the non-MPE group, patients with MPE were older, had higher serum LDH, sLDH/pADA, and CRp (all p <0.05). They also had a lower pleural neutrophil ratio and ADA (all p <0.05). For sLDH/pADA, the optimal cut-off value was 20, yielding an AUC of 0.85 with 85% sensitivity and 79% specificity. For CRp, the optimal threshold was 18, corresponding to an AUC of 0.72, 73% sensitivity, and 58% specificity.
Conclusion: sLDH/pADA showed high sensitivity and good diagnostic value for identifying MPE, while CRp did not enhance accuracy. The findings support sLDH/pADA as a useful tool for distinguishing MPE, especially in tuberculosis-endemic regions.
References
1. Musso V, Diotti C, Palleschi A, Tosi D, Aiolfi A, Mendogni P. Management of pleural effusion secondary to malignant mesothelioma. J Clin Med. 2021;10(18):4247. doi: 10.3390/jcm10184247.
2. Yang L, Wang Y. Malignant pleural effusion diagnosis and therapy. Open Life Sci. 2023;18(1):20220575. doi: 10.1515/biol-2022-0575.
3. Corcoran JP, Psallidas I, Wrightson JM, Hallifax RJ, Rahman NM. Pleural procedural complications: prevention and management. J Thorac Dis. 2015;7(6):1058-67. doi: 10.3978/j.issn.2072-1439.2015.04.42.
4. Vu-Hoai N, Le-Phu NT, Nguyen-Dang K, et al. The diagnostic value of liquid-based cytology of pleural fluid in malignant pleural effusion: A prospective study. Biomed Res Ther. 2025;12(2):7125-30. doi: 10.15419/bmrat.v12i2.957.
5. Verma A, Abisheganaden J, Light RW. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio). Lung. 2016;194(1):147-53. doi: 10.1007/s00408-015-9831-6.
6. Zhang F, Hu L, Wang J, Chen J, Chen J, Wang Y. Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion. J Clin Lab Anal. 2017;31(5)doi: 10.1002/jcla.22106.
7. Verma A, Dagaonkar RS, Marshall D, Abisheganaden J, Light RW. Differentiating Malignant from Tubercular Pleural Effusion by Cancer Ratio Plus (Cancer Ratio: Pleural Lymphocyte Count). Can Respir J. 2016;2016:7348239. doi: 10.1155/2016/7348239.
8. Gayaf M, Anar C, Canbaz M, Tatar D, Güldaval F. Value of Cancer Ratio plus and Cancer Ratio Formulation in Distinguishing Malignant Pleural Effusion from Tuberculosis and Parapneumonic Effusion. Tanaffos. 2021;20(3):221-231.
9. Nguyen QH, Nguyen TVA, Bañuls AL. Multi-drug resistance and compensatory mutations in Mycobacterium tuberculosis in Vietnam. Trop Med Int Health. 2025;doi: 10.1111/tmi.14104.
10. Chalamalasetty SP, Acharya P, Antony T, Ramakrishna A, Kotian H. The Use of "Cancer Ratio" in Differentiating Malignant and Tuberculous Pleural Effusions: Protocol for a Prospective Observational Study. JMIR Res Protoc. 2024;13:e56592. doi: 10.2196/56592.
11. Akoglu H. User's guide to sample size estimation in diagnostic accuracy studies. Turk J Emerg Med. 2022;22(4):177-185. doi: 10.4103/2452-2473.357348.
12. Tian P, Qiu R, Wang M, et al. Prevalence, Causes, and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China. JAMA Network Open. 2021;4(8):e2120306-e2120306. doi: 10.1001/jamanetworkopen.2021.20306.
13. Light RW. The Light criteria: the beginning and why they are useful 40 years later. Clin Chest Med. 2013;34(1):21-6. doi: 10.1016/j.ccm.2012.11.006.
14. Chan KKP, Lee YCG. Tuberculous pleuritis: clinical presentations and diagnostic challenges. Curr Opin Pulm Med. 2024;30(3):210-216. doi: 10.1097/mcp.0000000000001052.
15. Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis. 2007;45(11):1480-6. doi: 10.1086/522996.
16. Chen DY, Huang YH, Chen YM, et al. ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies. Lupus Sci Med. 2021;8(1)doi: 10.1136/lupus-2021-000562.
17. Bhatnagar M, Fisher A, Ramsaroop S, Carter A, Pippard B. Chylothorax: pathophysiology, diagnosis, and management-a comprehensive review. J Thorac Dis. 2024;16(2):1645-1661. doi: 10.21037/jtd-23-1636.
18. Kumar P, Gupta P, Rana S. Thoracic complications of pancreatitis. JGH Open. 2019;3(1):71-79. doi: 10.1002/jgh3.12099.
19. Nguyen-Dang K, Bui-Thi HD, Duong-Minh N, et al. The Role and Associated Factors of Liquid-Based Cytology of Bronchoalveolar Lavage Fluid in Lung Cancer Diagnosis: A Prospective Study. Cureus. 2023;15(11):e48483. doi: 10.7759/cureus.48483.
20. Tran-Le QK, Thai TT, Tran-Ngoc N, et al. Lung ultrasound for the diagnosis and monitoring of pneumonia in a tuberculosis-endemic setting: a prospective study. BMJ Open. 2025;15(4):e094799. doi: 10.1136/bmjopen-2024-094799.
21. Blackmore CC, Black WC, Dallas RV, Crow HC. Pleural fluid volume estimation: a chest radiograph prediction rule. Acad Radiol. 1996;3(2):103-9. doi: 10.1016/s1076-6332(05)80373-3.
22. Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75(1):25-36. doi: 10.4097/kja.21209.
23. Gonnelli F, Hassan W, Bonifazi M, et al. Malignant pleural effusion: current understanding and therapeutic approach. Respir Res. 2024;25(1):47. doi: 10.1186/s12931-024-02684-7.
24. Ishimoto O, Saijo Y, Narumi K, et al. High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology. 2002;63(1):70-5. doi: 10.1159/000065723.
25. Poon IK, Chan RCK, Choi JSH, et al. A comparative study of diagnostic accuracy in 3026 pleural biopsies and matched pleural effusion cytology with clinical correlation. Cancer Med. 2023;12(2):1471-1481. doi: 10.1002/cam4.5038.
26. Kassirian S, Hinton SN, Cuninghame S, et al. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis. Thorax. 2023;78(1):32-40. doi: 10.1136/thoraxjnl-2021-217959.
27. Kaul V, McCracken DJ, Rahman NM, Epelbaum O. Contemporary Approach to the Diagnosis of Malignant Pleural Effusion. Ann Am Thorac Soc. 2019;16(9):1099-1106. doi: 10.1513/AnnalsATS.201902-189CME.
28. Shipman AR, Bahrani S, Shipman KE. Investigative algorithms for disorders affecting plasma lactate dehydrogenase: a narrative review. J Lab Precis Med. 2024;9
29. Zeng T, Ling B, Hu X, et al. The Value of Adenosine Deaminase 2 in the Detection of Tuberculous Pleural Effusion: A Meta-Analysis and Systematic Review. Can Respir J. 2022;2022:7078652. doi: 10.1155/2022/7078652.
30. Antonangelo L, Faria CS, Sales RK. Tuberculous pleural effusion: diagnosis & management. Expert Rev Respir Med. 2019;13(8):747-759. doi: 10.1080/17476348.2019.1637737.
31. Wang J, Liu J, Xie X, Shen P, He J, Zeng Y. The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions. BMC Pulm Med. 2017;17(1):168. doi: 10.1186/s12890-017-0526-z.
32. Kulandaisamy PC, Kulandaisamy S, Kramer D, McGrath C. Malignant Pleural Effusions-A Review of Current Guidelines and Practices. J Clin Med. 2021;10(23)doi: 10.3390/jcm10235535.
33. Korczyński P, Mierzejewski M, Krenke R, Safianowska A, Light RW. Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions. Pol Arch Intern Med. 2018;128(6):354-361. doi: 10.20452/pamw.4278.
34. Shimoda M, Hirata A, Tanaka Y, et al. Characteristics of pleural effusion with a high adenosine deaminase level: a case–control study. BMC Pulm Med. 2022;22(1):359. doi: 10.1186/s12890-022-02150-4.
35. Lee J, Park J, Lim JK, et al. Tuberculous and Malignant Pleural Effusions With Adenosine Deaminase Levels of 40–70 IU/L: Trends in New Cases Over Time and Differentiation Between Groups. J Korean Med Sci. 2025;40(13)
36. Terra RM, Antonangelo L, Mariani AW, de Oliveira RL, Teixeira LR, Pego-Fernandes PM. Pleural Fluid Adenosine Deaminase (ADA) Predicts Survival in Patients with Malignant Pleural Effusion. Lung. 2016;194(4):681-6. doi: 10.1007/s00408-016-9891-2.
37. Ashchi M, Golish J, Eng P, O'Donovan P. Transudative malignant pleural effusions: prevalence and mechanisms. South Med J. 1998;91(1):23-6. doi: 10.1097/00007611-199801000-00004.
38. Assi Z, Caruso JL, Herndon J, Patz EF, Jr. Cytologically proved malignant pleural effusions: distribution of transudates and exudates. Chest. 1998;113(5):1302-4. doi: 10.1378/chest.113.5.1302.
39. Huang JH, Chen H, Zhang ZC, et al. Age affects the diagnostic accuracy of the cancer ratio for malignant pleural effusion. BMC Pulm Med. 2023;23(1):198. doi: 10.1186/s12890-023-02475-8.
Downloads
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
